Core Viewpoint - Zenas BioPharma, a clinical-stage biopharmaceutical company, has announced the pricing of a $200 million public offering of convertible senior notes and a $100 million equity offering, aiming to raise approximately $287.5 million in net proceeds to support its product development and commercialization efforts [1][2]. Group 1: Offerings Details - The company is offering $200 million in 2.50% convertible senior notes due 2032 and 5 million shares of common stock at $20.00 per share [1]. - The net proceeds from both offerings are estimated to be around $287.5 million after deducting underwriting discounts and expenses [2]. - The offerings are expected to close on March 31, 2026, subject to customary closing conditions [3]. Group 2: Convertible Notes Characteristics - The convertible notes will be unsecured senior obligations, accruing interest at 2.50% per year, with a maturity date of April 1, 2032 [4]. - Noteholders can convert their notes under certain conditions, with an initial conversion rate of 37.7358 shares per $1,000 principal amount, equating to a conversion price of approximately $26.50 per share [5]. - The notes are redeemable at the company's option after April 8, 2030, under specific conditions related to the stock price [6]. Group 3: Use of Proceeds - The company intends to use the proceeds to support the U.S. commercial launch of obexelimab for IgG4-RD treatment, advance its development pipeline, and for general corporate purposes [8]. Group 4: Company Overview - Zenas BioPharma focuses on developing transformative therapies for autoimmune diseases, with key products including obexelimab and orelabrutinib [13]. - Obexelimab is designed to inhibit pathogenic B cells without depleting them, while orelabrutinib targets B cells in both peripheral and central nervous systems [13].

Core Viewpoint - Zenas BioPharma, a clinical-stage biopharmaceutical company, has initiated underwritten public offerings for convertible senior notes due 2032 and shares of its common stock to support its commercial launch and development pipeline for autoimmune disease therapies [1][5]. Offering Details - The company is offering convertible senior notes with a maturity date of April 1, 2032, and will pay interest semi-annually [4]. - Underwriters will have a 30-day option to purchase an additional 15% of the convertible notes and shares of common stock to cover over-allotments [2]. Use of Proceeds - The net proceeds from the offerings are intended to support the U.S. commercial launch of obexelimab for IgG4-RD treatment, advance the development pipeline, and cover working capital and general corporate purposes [5]. Company Overview - Zenas BioPharma focuses on developing transformative therapies for autoimmune diseases, with lead candidates including obexelimab and orelabrutinib [10]. - Obexelimab is designed to inhibit pathogenic B cells without depleting them, while orelabrutinib targets B cells in both peripheral and central nervous systems [10].

Core Insights - ENAVATE Sciences GP, LLC increased its stake in Zenas BioPharma by purchasing 157,800 shares, valued at approximately $5.19 million based on quarterly average pricing [2][6] - The value of Zenas BioPharma's position in ENAVATE's portfolio rose by $58.80 million during the quarter, reflecting both the share purchase and stock price appreciation [2][6] - Zenas BioPharma now constitutes 28.08% of ENAVATE's reportable assets under management (AUM), making it the largest holding in the fund [6][7] Company Overview - Zenas BioPharma is a clinical-stage biotechnology company focused on developing therapies for autoimmune and rare immunological diseases [6][8] - The company has a pipeline that includes several monoclonal antibodies and fusion proteins aimed at addressing significant unmet medical needs [9] - As of March 20, 2026, Zenas BioPharma's stock price was $22.30, reflecting a 167% increase compared to one year prior, significantly outperforming the S&P 500 [7] Financial Metrics - As of the latest market close, Zenas BioPharma's market capitalization is approximately $932.9 million, with a trailing twelve months (TTM) revenue of $10 million and a TTM net income of -$377.7 million [4] - After the recent purchase, ENAVATE holds a total of 3,919,159 shares of Zenas BioPharma, valued at $142.30 million at quarter-end [6][10] Strategic Insights - ENAVATE's investment strategy focuses on high-conviction positions in specific biotech companies, rather than diversifying across a broad range of investments [11] - Zenas BioPharma is expected to submit a Biologics License Application (BLA) to the FDA for its lead candidate obexelimab in Q2 2026, with significant upcoming data releases that could impact its valuation [12]

Core Insights - Zenas BioPharma is preparing to submit marketing applications for obexelimab for IgG4-RD to the FDA in Q2 2026 and to the EMA in H2 2026, following positive Phase 3 INDIGO trial results [1][4] - The company anticipates topline results from the Phase 2 SunStone trial for systemic lupus erythematosus (SLE) in Q4 2026 [1][4] - Zenas has secured up to $250 million in non-dilutive debt financing from Pharmakon, enhancing its financial flexibility for commercialization and pipeline investments [1][6] Corporate Highlights - Obexelimab is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, showing a 56% reduction in IgG4-RD flare risk compared to placebo in the INDIGO trial [4][12] - The company is advancing multiple pipeline programs, including orelabrutinib for multiple sclerosis (MS) and ZB021, an oral IL-17AA/AF inhibitor, with Phase 1 trials expected to start in Q2 2026 [2][3][7] - ZB014, a new half-life extended anti-CD-19 and FcγRIIb antibody, is also progressing toward clinical development [3][4] Financial Results - For the year ended December 31, 2025, Zenas reported revenue of $10 million, primarily from a license agreement, compared to $5 million in 2024 [10][11] - Research and development expenses increased to $168.1 million in 2025 from $139.1 million in 2024, driven by higher personnel and clinical trial costs [13][21] - The net loss for the year was $377.7 million, compared to a net loss of $157.0 million in 2024 [13][21] Balance Sheet - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $360.5 million, up from $350.8 million in 2024 [22] - Total liabilities increased to $141.5 million from $57.5 million in 2024, reflecting the new debt facility [22] - The accumulated deficit reached $765.1 million as of December 31, 2025, compared to $387.4 million in 2024 [22]

Core Thesis - Zenas BioPharma, Inc. is viewed positively due to its transition from a pre-revenue stage to commercialization, with projected revenues rising to $30 million by 2026 and significant growth thereafter [2][5] Company Overview - Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies [2] - The company's lead asset, obexelimab, targets IgG4-Related Disease (IgG4-RD), a market currently lacking approved therapies, providing a unique at-home treatment option [2] Product Potential - Obexelimab's mechanism via CD19/FcγRIIb preserves patients' immune systems, presenting a potential competitive advantage, although recent trial data indicated efficacy may not meet "best-in-class" expectations [3] - The drug is also being tested for Warm Autoimmune Hemolytic Anemia and Multiple Sclerosis, positioning Zenas for a long-term role in treating B-cell-mediated autoimmune diseases [3] Financial Position - As of early 2026, Zenas had approximately $270 million in cash, which is expected to support operations through 2028 [4] - The company has expanded its pipeline through in-licensing strategies, reducing early-stage discovery risks [4] Market Valuation - Current market focus on hazard ratio metrics may undervalue ZBIO, which is trading at a significant discount to its potential [5] - With successful regulatory filings and commercialization, Zenas could achieve a market capitalization up to five times its current value, indicating a high-risk, high-reward investment opportunity [5]

Summary of Zenas BioPharma Conference Call Company Overview - **Company**: Zenas BioPharma (NasdaqGS: ZBIO) - **Event**: Guggenheim Emerging Outlook Biotech Summit 2026 - **Date**: February 11, 2026 Key Points on IgG4-RD and Obexelimab - **Pipeline Focus**: The primary focus is on obexelimab and its application in IgG4-related disease (IgG4-RD) [2][3] - **INDIGO Phase 3 Study Results**: - Reported a **56% risk reduction** in time to disease flare with a hazard ratio of **0.4** [3] - Approximately **75% of patients** were free from flares, indicating strong efficacy [3] - In the open-label extension, **92% of evaluable patients** remained flare-free at six months [4] - **Safety Profile**: - Serious adverse events were comparable to placebo, with no significant increase in infections [4][5] - The subcutaneous administration showed similar injection site reactions to placebo, enhancing its safety profile [5] Market Research Insights - **Market Research Study**: Conducted with **80 participants**, primarily rheumatologists and gastroenterologists [6] - **Prescribing Likelihood**: - **64%** of physicians indicated they would likely prescribe obexelimab [8] - Expected market share allocation: **47%** for obexelimab, with the remainder split between Uplizna and rituximab [8] - **Patient Population Insights**: - Physicians reported treating an average of **18 patients** per year with IgG4-RD [6] - The drug is seen as suitable for older patients or those with concurrent illnesses [9] Commercialization Strategy - **Market Opportunity**: Estimated market size for IgG4-RD treatment in the U.S. is between **$3-$4 billion**, with expectations for obexelimab to exceed **$1 billion** in sales [41][42] - **Patient Population**: Approximately **20,000 diagnosed patients** in the U.S. currently, with potential for growth through increased education and diagnosis [40] - **Launch Timeline**: - BLA filing expected in **Q2 2026** for the U.S. and in the second half of the year for Europe [56] - Initial launch will feature prefilled syringes, followed by an autoinjector within a year [56] Lupus Program Insights - **Sunstone Study**: - Results expected in **Q4 2026**, focusing on the **BICLA primary endpoint** [62] - Emphasis on strict screening criteria to ensure a pure patient population for accurate results [65] - **Biomarker Program**: A gene pattern identified in **30% of lupus patients** may indicate higher responsiveness to treatment [80] BTK Inhibitor Insights - **Orelibrutinib**: Positioned as a potent option for progressive MS, with ongoing trials to demonstrate its efficacy [90] - **Comparison with Competitors**: Fenebrutinib showed promising results compared to Ocrevus, indicating a competitive landscape for BTK inhibitors [88] Future Developments - **New Molecules**: - TYK2 and IL-17 oral molecules are set to enter clinical trials soon, with promising characteristics noted [95][97] - **Rapid Development**: The IL-17 molecule is expected to move quickly through clinical phases, with outcomes anticipated by the end of the year [97] Conclusion - Zenas BioPharma is positioned to capitalize on its robust pipeline, particularly with obexelimab for IgG4-RD, and is preparing for significant market entry and expansion in the coming years. The company is also actively pursuing additional indications, including lupus and progressive MS, with a focus on safety and efficacy in patient populations.

Core Insights - Obexelimab demonstrated a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo in the Phase 2 MoonStone trial, indicating significant efficacy in treating Relapsing Multiple Sclerosis (RMS) [1][2] - The 24-week data further confirmed the drug's robust and durable activity, maintaining significant reductions in lesions and improving biomarkers associated with disease activity [3][4] - The safety profile of obexelimab was consistent with previous trials, showing good tolerability without new safety signals [2][3] Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [12] - The company is advancing two late-stage product candidates: obexelimab and orelabrutinib, with obexelimab being the lead candidate targeting B cell activity [12] - Zenas plans to submit a Biologics License Application (BLA) for obexelimab in the second quarter of 2026 and a Marketing Authorization Application (MAA) in the second half of 2026 for Immunoglobulin G4-Related Disease [11][12] Clinical Trial Details - The Phase 2 MoonStone trial enrolled 116 patients and was designed to evaluate the efficacy and safety of obexelimab in RMS, using MRI endpoints to measure treatment outcomes [9] - The trial's primary endpoint was the cumulative number of new gad-enhancing T1 lesions over weeks 8 and 12, with secondary endpoints assessing disease progression through various biomarkers [9] - Following the double-blind phase, patients transitioned to an open-label period to continue treatment and assess long-term outcomes [9] Mechanism of Action - Obexelimab is a bifunctional monoclonal antibody that binds to CD19 and FcγRIIb, inhibiting B cell activity without depleting them, which is crucial for addressing autoimmune diseases [10][12] - The drug's unique mechanism and self-administered subcutaneous injection regimen may effectively target the pathogenic role of B cells in chronic autoimmune conditions [10][12]

Core Insights - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [3] - The company will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026 [1] Company Overview - Zenas aims to lead in the development and commercialization of therapies for autoimmune diseases, leveraging an experienced leadership team and a disciplined product candidate acquisition strategy [3] - The company is advancing two late-stage product candidates: obexelimab and orelabrutinib [3] - Obexelimab is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, designed to inhibit pathogenic B cells without depleting them [3] - Orelabrutinib is a selective CNS-penetrant oral small molecule BTK inhibitor that targets pathogenic B cells in both peripheral and central nervous systems [3] - Zenas also has earlier stage programs, including ZB021, an oral IL-17AA/AF inhibitor, and ZB022, a brain-penetrant TYK2 inhibitor [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Zenas BioPharma, Inc. and its officers or directors, following disappointing results from a clinical trial that negatively impacted the company's stock price [1][3]. Group 1: Company Overview - Zenas BioPharma, Inc. is a publicly traded company on NASDAQ under the ticker ZBIO [1]. - The company recently announced results from the Phase 3 INDIGO trial of its drug obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) [3]. Group 2: Trial Results and Market Reaction - The trial results were characterized as "positive" by Zenas; however, analysts indicated that the drug's efficacy did not meet the necessary threshold for commercial viability [3]. - Following the announcement, Zenas's stock price dropped by $17.89 per share, or 51.86%, closing at $16.61 on January 5, 2026 [3]. - On a subsequent conference call, the CEO expressed disappointment regarding the drug's hazard ratio, which did not meet expectations, leading to an additional stock price decline of $1.41 per share, or 8.49%, closing at $15.20 on January 6, 2026 [4].

Core Viewpoint - Zenas BioPharma, Inc. is under investigation for potential securities fraud following disappointing results from a clinical trial, which led to significant stock price declines [1][2][3]. Group 1: Company Overview - Zenas BioPharma, Inc. trades on NASDAQ under the ticker ZBIO [1]. - The company recently announced results from the Phase 3 INDIGO trial of obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) [2]. Group 2: Trial Results and Market Reaction - The trial results were characterized as "positive" by Zenas, but analysts indicated that the drug's efficacy did not meet the necessary threshold for commercial viability [2]. - Following the announcement, Zenas's stock price dropped by $17.89 per share, or 51.86%, closing at $16.61 on January 5, 2026 [2]. - On a subsequent conference call, the CEO expressed disappointment regarding the hazard ratio, which did not meet expectations, resulting in an additional stock price decline of $1.41 per share, or 8.49%, closing at $15.20 on January 6, 2026 [3].